{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"16","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Overall response rate was defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) among all eligible and treated patients. Best overall response was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. The 90% two-sided binomial exact confidence interval was calculated for ORR.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Subprotocol R"}],"paramType":"NUMBER","populationDescription":"eligible and treated patients","reportingStatus":"POSTED","timeFrame":"assessed at baseline, then every 2 cycles until disease progression, up to 3 years post registration","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}